News

/News/

Pfizer to hike list price of 41 medicines

Article written by: Joe Barber

Pfizer has announced that it plans to increase the list price of 41 medicines, or 10 percent of its entire drug portfolio, as of January 15. The company indicated that “the increase in list price to this subset of [our] portfolio will be 5 percent,” with the only exceptions being three drugs, which will see their prices rise 3 percent, and one other product, whose cost will jump 9 percent. List prices for the remainder of the portfolio will be unchanged, the drugmaker said.

Read full article here: https://goo.gl/uZ7A5d

 

 

By |2018-11-19T11:11:12+00:00November 19th, 2018|News|0 Comments

Remap team presenting their research at ISPOR Barcelona

The team at Remapconsulting are proud to be presenting 3 of their posters today and are looking forward to discussing their research

K30: DO COMPANIES’ MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY’S COMPLEX PAYER MARKETPLACE? https://goo.gl/RRbWtD

N34: WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU? https://goo.gl/6Sv6Sm

O13: EXPLORING BIOSIMILAR MARKET ACCESS CONSIDERATIONS ACROSS EUROPE https://goo.gl/SQsYWx

By |2018-11-13T08:56:57+00:00November 13th, 2018|News|0 Comments

Remap are to present 5 research posters at ISPOR 2018

The team at Remap Consulting will be presenting 5 research posters at the #ISPOR congress in Barcelona next week.

Come along and meet the team at booth 901, discuss our findings or have a chat about your pricing and market access challenges.

Looking forward to seeing you there.

 

By |2018-11-06T15:14:20+00:00November 6th, 2018|News|0 Comments

How is patient access to high-cost orphan drugs changing?

Patient access to high-cost orphan drugs. How have the Netherlands and Scotland recently adjusted their approach?

The number of drugs approved for the treatment of orphan diseases is increasing in Europe, driven by various regulatory and financial incentives. Orphan drugs have important societal value as they improve patient quality of life and address unmet medical need; however, the high prices of these drugs and their often-weaker clinical data packages presents a challenge to health care systems across Europe. In this newsletter we highlight recent changes to the reimbursement processes for high-cost orphan drugs in the Netherlands and Scotland.

Drug pricing pressure in Dutch hospitals

The cost of hospital drugs in the Netherlands has been a hot topic for several years. In 2013, the Dutch Health Authority stated that hospital drug costs had increased from €690m in 2010 to €1,530m in 2013[1]. In the 2016 Medicines Plan of the Ministry of Health, […]

By |2018-10-24T14:00:54+00:00October 24th, 2018|News|0 Comments

Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?

Since 29 July 2016, the NICE appraisal process for oncology indications in England has been modified to allow one of three outcomes; recommended for routine use, not recommended, or recommended within the Cancer Drugs Fund (CDF) managed access scheme. This study investigates the outcomes of NICE appraisals for new cancer drugs assessed via the modified process.

Read our findings here…… (Is the new NICE appraisal process too positive?)

By |2018-10-19T15:05:25+00:00October 19th, 2018|Publications|0 Comments